Research programme: CNS and metabolic disorders therapeutics - BioFocus/Biovitrum

Drug Profile

Research programme: CNS and metabolic disorders therapeutics - BioFocus/Biovitrum

Alternative Names: GPCR modulators - BioFocus/Biovitrum; Serotonin 2a receptor antagonists - BioFocus/Biovitrum

Latest Information Update: 15 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioFocus DPI; Biovitrum
  • Class
  • Mechanism of Action G protein-coupled receptor modulators; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued CNS disorders; Major depressive disorder; Obesity

Most Recent Events

  • 31 Mar 2014 BioFocus DPI has been acquired by Charles River Laboratories
  • 29 Jul 2005 Discontinued - Preclinical for CNS disorders in Europe (unspecified route)
  • 29 Jul 2005 Discontinued - Preclinical for Depression in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top